Literature DB >> 1988523

Recovery of human immunodeficiency virus type 1 from semen: minimal impact of stage of infection and current antiviral chemotherapy.

J N Krieger1, R W Coombs, A C Collier, S O Ross, K Chaloupka, D K Cummings, V L Murphy, L Corey.   

Abstract

Because exposure to semen is important for the sexual transmission of human immunodeficiency virus type 1 (HIV), the relationship of stage of infection and antiviral chemotherapy to isolation of HIV from semen was investigated. Whereas HIV was isolated from peripheral blood mononuclear cells of all seropositive persons tested, it was isolated from semen in only 11 (32%) of 34 men, including 3 of 6 who were studied sequentially over time. HIV was isolated from 6 (32%) of 19 semen specimens from 14 asymptomatic persons (Centers for Disease Control [CDC] class II or III) and from 10 (28%) of 36 semen specimens from 20 symptomatic patients (CDC class IV). Isolation of HIV from semen did not correlate with CD4+ or CD8+ T lymphocytes counts or zidovudine therapy. Seropositive men may shed HIV in semen early in the course of infection, and zidovudine therapy seems to have no effect on the recovery of HIV and, thus, on the potential for sexual transmission of HIV.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1988523     DOI: 10.1093/infdis/163.2.386

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  23 in total

Review 1.  Antiretroviral drug concentrations in semen of HIV-1 infected men.

Authors:  S Taylor; A S Pereira
Journal:  Sex Transm Infect       Date:  2001-02       Impact factor: 3.519

Review 2.  Antiretroviral-drug concentrations in semen: implications for sexual transmission of human immunodeficiency virus type 1.

Authors:  A D Kashuba; J R Dyer; L M Kramer; R H Raasch; J J Eron; M S Cohen
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

3.  High viral load in semen of human immunodeficiency virus type 1-infected men at all stages of disease and its reduction by therapy with protease and nonnucleoside reverse transcriptase inhibitors.

Authors:  P Gupta; J Mellors; L Kingsley; S Riddler; M K Singh; S Schreiber; M Cronin; C R Rinaldo
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

4.  Multicenter evaluation of methods to quantitate human immunodeficiency virus type 1 RNA in seminal plasma.

Authors:  S A Fiscus; D Brambilla; R W Coombs; B Yen-Lieberman; J Bremer; A Kovacs; S Rasheed; M Vahey; T Schutzbank; P S Reichelderfer
Journal:  J Clin Microbiol       Date:  2000-06       Impact factor: 5.948

5.  Presence of human immunodeficiency virus nucleic acids in wastewater and their detection by polymerase chain reaction.

Authors:  S A Ansari; S R Farrah; G R Chaudhry
Journal:  Appl Environ Microbiol       Date:  1992-12       Impact factor: 4.792

Review 6.  Antiviral therapy: current concepts and practices.

Authors:  B Bean
Journal:  Clin Microbiol Rev       Date:  1992-04       Impact factor: 26.132

Review 7.  Targeting Trojan Horse leukocytes for HIV prevention.

Authors:  Deborah J Anderson; Joseph A Politch; Adam M Nadolski; Caitlin D Blaskewicz; Jeffrey Pudney; Kenneth H Mayer
Journal:  AIDS       Date:  2010-01-16       Impact factor: 4.177

8.  Detection of feline immunodeficiency virus in semen from seropositive domestic cats (Felis catus).

Authors:  H L Jordan; J Howard; W A Tompkins; S Kennedy-Stoskopf
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

9.  HIV-1 nucleic acids localize to the spermatogonia and their progeny. A study by polymerase chain reaction in situ hybridization.

Authors:  G J Nuovo; J Becker; A Simsir; M Margiotta; G Khalife; M Shevchuk
Journal:  Am J Pathol       Date:  1994-06       Impact factor: 4.307

10.  Prior mucosal exposure to heterologous cells alters the pathogenesis of cell-associated mucosal feline immunodeficiency virus challenge.

Authors:  Surender B Kumar; Sarah Leavell; Kyle Porter; Barnabe D Assogba; Mary J Burkhard
Journal:  Retrovirology       Date:  2010-05-28       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.